FP124SURVIVAL MODEL IN PATIENTS WITH RENAL AMYLOIDOSIS

Authors:

Abstract
INTRODUCTION AND AIMS: New therapeutic strategies for AL Amyloidosis with bortezomib and lenalidomide have improved the prognosis. The aim of our study was to evaluate the outcome as renal and patient survival in a population with renal AL Amyloidosis after cycles of Bortezomib + Cyclophosphamide + Dexamethasone (BCD) and Lenalidomide.